Screening for primary aldosteronism using the newly developed IDS-iSYS® automated assay system  by O’Shea, P.M. et al.
Contents lists available at ScienceDirect
Practical Laboratory Medicine
journal homepage: www.elsevier.com/locate/plabm
Screening for primary aldosteronism using the newly developed
IDS-iSYS® automated assay system
P.M. O’Sheaa,⁎, T.P. Griﬃnb, G.A. Brownec, N. Gallaghera, J.J. Bradye,
M.C. Dennedyb,c, M. Bellb, D. Walld, M. Fitzgibbone
a Department of Clinical Biochemistry, Galway University Hospitals, Galway, Ireland
b Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland
c Discipline of Pharmacology & Therapeutics, School of Medicine, National University of Ireland, Galway, Ireland
d School of Mathematics, Statistics and Applied Mathematics, National University of Ireland, Galway, Ireland
e Department of Clinical Biochemistry & Diagnostic Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland
A R T I C L E I N F O
Keywords:
Primary aldosteronism
Renin
Aldosterone
Aldosterone: renin ratio (ARR)
Sensitivity
Speciﬁcity
A B S T R A C T
Background: The recommended approach to screening for primary aldosteronism (PA) in at-
risk populations is to determine the ratio of aldosterone concentration (serum (SAC)/plasma
(PAC)) to renin measured in plasma as activity (PRA) or concentration (DRC). However, lack of
assay standardisation mandates the need for method-speciﬁc decision thresholds and clinical
validation in the local population.
Aim: The study objective was to establish method-speciﬁc aldosterone: renin ratio (ARR) cut-
oﬀs for PA in men and women using the IDS-iSYS® assay system (IDS plc).
Methods: A prospective cohort study design was used. PAC and DRC were measured
immunochemically in ethylenediamine-tetraacetic acid (EDTA) plasma on the IDS-iSYS®
instrument.
Results: A total of 437 subjects (218 men, 219 women) were recruited including: healthy
normotensive volunteers (n=266) and women taking the oral contraceptive pill (OCP; n=15);
patients with essential hypertension (EH; n=128); conﬁrmed PA (n=16); adrenal cortical
carcinoma (ACC; n=3); Addison's disease (AD; n=4) and phaeochromocytoma/paraganglioma
(PPGL; n=5). In this population, an ARR cut-oﬀ at >37.4 pmol/mIU provided 100% diagnostic
sensitivity, 96% speciﬁcity and positive likelihood ratio for PA of 23:1. When the ARR decision
threshold was stratiﬁed according to gender, a cut-oﬀ of >26.1 pmol/mIU in men and
>113.6 pmol/mIU in women resulted in diagnostic sensitivity and speciﬁcity of 100%.
Conclusion: This study demonstrates that decision thresholds for PA should not only be
method-speciﬁc but also gender-speciﬁc. However, given the small number of PA patients
(n=16), particularly women (n=4), further validation through a prospective study with a larger
PA cohort is required before the thresholds presented here could be recommended for routine
clinical use.
1. Introduction
Primary aldosteronism (PA), ﬁrst described by Jerome Conn [1], is a group of adrenal disorders in which aldosterone production
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is inappropriately high for sodium status, relatively independent of angiotensin II stimulation and nonsuppressible by sodium
loading [2]. Prevalence rates in hypertensive populations vary from 3% to 32% [3–6]. Patients with PA have higher cardiovascular
morbidity and mortality than age-, gender- and blood pressure- (BP) matched subjects with essential hypertension [7,8]. Timely
identiﬁcation is likely to lead to better outcome as speciﬁc management has been shown in observational studies to improve the
impact of this condition on key patient outcomes [7,9,10]. The recommended approach to screening for PA in at-risk populations is
to determine the aldosterone-to-renin ratio (ARR)[2,11]. The ARR is calculated from the concentration of aldosterone in serum
(serum aldosterone concentration, SAC) or plasma (plasma aldosterone concentration, PAC) divided by plasma renin measured
either as renin activity (PRA) or direct renin concentration (DRC)[11]. However, measurement of aldosterone and renin is
analytically challenging, with several method combinations for both analytes in routine clinical use. This situation is further
compounded by the lack of assay standardisation and the use of diﬀerent reporting units for both aldosterone (ng/dL, ng/L, pg/mL
and pmol/L) and renin (PRA: ng/mL/h, nmol/L/h and pmol/L/min; DRC: μIU/mL, mIU/L and ng/L). This underlies the need for
method-speciﬁc decision thresholds and clinical validation in the local population.
The recent Endocrine Society Clinical Practice Guideline (ESCPG) for the management of PA provides assay-dependent ARR
decision threshold values reﬂecting the use of renin activity and concentration, and expressed using diﬀerent reporting units [2].
Notably, this table is unchanged from that previously published in 2008 [11]. From a clinical perspective this is challenging, as
signiﬁcant methodological improvements have occurred in the intervening eight years. There is no reference to clinical validation
studies using these newer assays [12,13]. Moreover, it is often not appreciated that indiscriminate adoption of the ESCPG cut-oﬀs
has the potential to incorrectly classify patients [14].
Using the newly developed Immunodiagnostics Systems Speciality Immunoassay Automated System (IDS-iSYS® system; IDS
plc, Boldon, UK) for aldosterone and renin measurement, we demonstrated that reference intervals for aldosterone, renin and the
ARR are gender-speciﬁc [15]. The ﬁnding of signiﬁcant diﬀerences between genders is an important consideration in relation to how
these reference intervals are applied in the stratiﬁcation of patients with refractory hypertension and optimisation of therapeutic
management of patients with hypertension. The objective of this study was to establish method-speciﬁc ARR cut-oﬀs for PA in men
and women using the IDS-iSYS® assay system.
2. Methods
Research ethics approval for this collaborative study was obtained in accordance with the Declaration of Helsinki and was
granted by each Institution's Clinical Research Ethics Committees prior to commencing patient recruitment.
2.1. Study design
2.1.1. Patient cohorts
A prospective cohort study design was conducted at the Centre for Endocrinology, Diabetes and Metabolism at Galway University
Hospital (GUH) between December 2014 and September 2015. Redundant ethylene diamine-tetracetic acid (EDTA) plasma from
patients presenting to GUH with hypertension (HTN; n=128) or an adrenal mass/pathology (n=28) and with an ARR requested was
utilised. Study subjects were investigated according to routine standard medical/diagnostic care [2,16–18]. Clinical details were
recorded on a standardised data collection form following chart review and interrogation of the electronic radiology and laboratory
information systems.
The inclusion criteria were: age ≥18years, non-pregnant and either exclusion or conﬁrmation of PA by standard criteria that were
necessarily independent of the biochemical tests being evaluated (speciﬁcally, the aldosterone response to the Saline Infusion Test
(SIT) or an established alternative diagnosis).
Those with speciﬁc diagnoses were included based on the following criteria:
PA: diagnosis conﬁrmed by pathological SIT i.e., PAC >140 pmol/L post the infusion of 2 L of normal saline (0.9% NaCl) over
4 h [12]: Phaeochromocytoma/Paraganglioma (PPGL)/Adrenal Cortical Carcinoma (ACC): diagnosis conﬁrmed histologically;
Addison's disease (AD): conﬁrmed by response to short synacthen test i.e., 30 min post synacthen cortisol <430 nmol/L (Method:
Cobas® Cortisol assay [Roche Diagnostics, Basel, Switzerland); Treated essential hypertension (EH): Type 2 Diabetes Mellitus
(T2DM) with haemoglobin A1C ≤75 mmol/mol on a minimum of 2 anti-HTN agents excluding β-blockers; Treatment-naïve EH:
non-diabetic with normal electrolytes and kidney function (Modiﬁcation of Diet in Renal Disease Study [MDRD] equation eGFR
>60 mL/min/1.73 m2). Not all patients in the treated EH or treatment-naïve EH groups had a SIT to deﬁnitively exclude PA. The
decision not to perform the SIT was based on the initial clinical presentation, the degree of hypertension and the number of
antihypertensive medications required to control the hypertension.
The exclusion criteria were: insuﬃcient sample volume ( <500 μL) or gross haemolysis/ lipaemia.
2.1.2. Healthy volunteers
Data for ARR from 266 participants recruited from the local population with the objective of establishing reference intervals for
PAC, DRC and the ARR and previously published were utilised in this study [15]. In brief, the inclusion criteria for healthy
volunteers were; age ≥18years, BMI ≤30 kg/m2, non-pregnant, BP <140/90 mm Hg, normal electrolytes and kidney function
(MDRD equation eGFR≥60 mL/min/1.73 m2), non-smoker, Irish Caucasian, and not taking prescribed/Over The Counter (OTC)
medications for a minimum of 3 months. In female participants of reproductive age, no record of the stage of the menstrual cycle was
taken at the time of sample collection.
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2.1.3. Healthy female volunteers taking the oral contraceptive pill (OCP)
A total of 15 healthy normotensive female volunteers were recruited from the local population. The inclusion criteria were
identical to that of the healthy volunteers except that these women had been taking the OCP for a minimum of 3 months.
2.2. Analytical methods
DRC and PAC were measured in EDTA plasma using the IDS/iSYS® Immunochemiluminometric assay (ICMA) platform. The
DRC assay is a sandwich ICMA employing two monoclonal antibodies, a magnetic particle solid-phase capture antibody and an
acridinium-labelled tag antibody. Concentration of renin is directly proportional to light (expressed in relative light units) emitted by
the acridinium label and measured by the system luminometer. The DRC assay is calibrated to the WHO International Standard 68/
356. The reportable range is 1.8 mIU/L to 550 mIU/L. The inter-assay imprecision expressed as coeﬃcients of variation (CVA%), at
mean DRCs of 14 mIU/L, 100.3 mIU/L and 390.2 mIU/L were 7.7%, 8.4% and 4.9%, respectively [15].
The PAC assay is a competitive one-site ICMA that uses a biotinylated monoclonal antibody bound to streptavidin-coated
magnetic particles. Acridinium-labelled aldosterone competes with sample aldosterone for the limited amount of biotinylated
antibody. Concentration of aldosterone is inversely proportional to light emitted by the acridinium label and measured by the system
luminometer. The IDS-iSYS® PAC assay is referenced to liquid chromatography-tandem mass spectrometry (LC-MS/MS). The
reportable range is 102 pmol/L to 3656 pmol/L. The between-run CVAs at mean aldosterone concentrations of 238 pmol/L,
442 pmol/L and 1648 pmol/L were 9.71%, 9.37% and 3.83%, respectively [15]. Results from each assay were used to calculate the
ARR as follows: Aldosterone in pmol/L divided by the DRC in mIU/L to give the ARR in pmol/mIU.
2.3. Laboratory sampling protocol for ARR
Routinely, biochemical testing for the ARR was carried out in ambulatory subjects with an unrestricted salt intake. Subjects were
required to attend clinic for phlebotomy between 07:00–12:00. All subjects were seated for 10–15 min prior to having whole blood
(10 mL) drawn and collected into appropriate specimen tubes (Becton Dickinson/Sarstedt plastic evacuated tubes containing EDTA
anticoagulant; Becton-Dickinson, Franklin Lakes, NJ, USA; Sarstedt, Numbrecht, Germany) for the measurement of PAC/DRC.
Specimen tubes were kept at room temperature (RT) and transported within 30 min of blood draw to the laboratory for immediate
processing (centrifugation, separation and freezing of plasma). EDTA plasma was stored in a temperature-controlled freezer at −20°
Celsius prior to batch analysis on the IDS-iSYS® instrument.
It is mandatory for clinical and medication details to be supplied on the laboratory request form. Prior to testing, the correction
of pre-existing hypokalaemia and where medically safe, the withdrawal of any agents that markedly interfere with the renin-
angiotensinogen-aldosterone system (RAAS) for a minimum of 6 weeks, i.e. renin inhibitors, mineralocorticoid receptor antagonists
and amiloride is recommended [19]. Further, as β-blocker therapy is associated with a signiﬁcant risk of false-positive ARR results
their withdrawal for 2 weeks prior to measurement of ARR using DRC [20] is recommended. Angiotensin converting enzyme
inhibitors and angiotensin II type 1 receptor blockers have the potential to cause false-negative ARR screens as these drugs lower
aldosterone and raise renin [21]. In such patients an undetectable renin makes PA highly likely. By contrast, should the renin be
detectable or the ARR low the diagnosis cannot be excluded [19]. In such instances ARR testing should be repeated having
substituted blood pressure lowering medications with agents that negligibly interfere with the RAAS. Drugs that can be used as an
alternative to control hypertension, and that minimally interfere with ARR include verapamil, doxazosin, prazosin hydrochloride and
hydralazine.
2.4. Statistical analysis
Statistical analysis was performed using R (V3.2.0 R Foundation for Statistical Computing; accessible at www.r-project.org).
Summary statistics for normally distributed continuous variables were given by mean (standard deviation) and frequencies
(percentages) for categorical variables. Data that was not normally distributed was presented as median (range). Results below the
limit of detection were set to each assay's respective analytical sensitivity (DRC=1.8 mIU/L and PAC=102 pmol/L). Median values
for DRC, PAC and ARR between the study cohorts were compared using Mann-Whitney nonparametric one-way analysis of variance
with Bonferroni correction for multiple comparisons post-test. A p-value <0.05 was deemed to be statistically signiﬁcant.
The clinical utility of the IDS-iSYS® PAC, DRC and ARR in the study cohort was assessed using Receiver Operator Characteristics
(ROC) curve analysis. The PAC, DRC and ARR values from those in whom PA was conﬁrmed were used in the ROC curve analysis
comparison with participants without PA to deﬁne the optimum IDS-iSYS® decision thresholds for each test. For each analyte, a ROC
curve was constructed from the relationship between true-positive and false-positive results (i.e., sensitivity versus 1-speciﬁcity) at
diﬀerent criterion values. The Area Under the Curve (AUC) of each test was calculated as it is the summary measure of the diagnostic
utility and is independent of reference limits. The AUC can be interpreted as the probability that a randomly selected individual from
the positive group has a test result indicating greater suspicion than that for a randomly chosen individual from the negative group.
The optimum AUC equals 1.0; in this instance the curve will reach the upper left corner of the plot. When the variable under study
cannot distinguish between those with and without disease the AUC will be equal to 0.5 (the ROC curve will coincide with the
diagonal).
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3. Results
A total of 546 participants from the local population were assessed for inclusion in this study (Fig. 1). 109 subjects were excluded
(95 did not meet the inclusion criteria and a further 14 due to insuﬃcient sample volume ( <500 μL) to perform the analysis of both
PAC and DRC). In total, 437 subjects (218 men, 219 women) were recruited including: healthy normotensive volunteers (n=266)
and women taking the oral contraceptive pill (OCP: n=15); treatment-naïve patients with essential hypertension (EH; n=21);
patients with EH and type 2 diabetes chronically treated with antihypertensive medications excluding β-blockers (EH+T2DM;
n=107); conﬁrmed PA (n=16); adrenal cortical carcinoma (ACC; n=3); Addison's disease (AD; n=4) and phaeochromocytoma/
paraganglioma (PPGL; n=5). Baseline clinical and biochemical parameters are outlined in Table 1.
Integrated comparison of sensitivity and speciﬁcity using ROC curves showed the diagnostic power of the ARR to be superior to
either PAC or DRC (Fig. 2). ROC analysis for DRC provided an AUC of 0.97. The best DRC decision threshold for predicting PA in
our study cohort was ≤14.2 mIU/L giving a diagnostic sensitivity and speciﬁcity of 100% and 84%, respectively and positive
likelihood ratio of 6.2:1. When stratiﬁed according to gender, a cut-oﬀ of ≤4.5 mIU/L in women and ≤14.2 mIU/L in men resulted in
a diagnostic sensitivity of 100% in both sexes and speciﬁcity of 98% and 89%, respectively.
In all subjects, a cut-oﬀ value for PAC >239 pmol/L resulted in a diagnostic sensitivity and speciﬁcity of 100% and 44%,
respectively and positive likelihood ratio for PA of 1.8:1. In men, this cut-oﬀ resulted in a moderate improvement in the probability
of PA to 2.0:1 (diagnostic sensitivity 100% and speciﬁcity 51%). In women, a cut-oﬀ for PAC of >602 pmol/L resulted in a likelihood
ratio for PA of 7.7:1 (diagnostic sensitivity and speciﬁcity of 100% and 87%, respectively).
ROC curve analysis performed on the total cohort determined that the ARR provided the highest diagnostic eﬃciency for PA with
an AUC of 0.99. An ARR cut-oﬀ in males and females of >37.4 pmol/mIU showed a diagnostic sensitivity and speciﬁcity of 100%
and 96% respectively and positive likelihood ratio for PA of 23:1 (Fig. 2). The signiﬁcance of the decision thresholds for PAC, DRC
and ARR between patients with PA, EH, non-PA adrenal pathologies and healthy volunteers is detailed in Table 2.
When the ARR was stratiﬁed according to gender this provided the optimum AUC (1.0) for both men and women. A cut-oﬀ of
>26.1 pmol/mIU in men and >113.6 pmol/mIU in women resulted in diagnostic sensitivity and speciﬁcity of 100%. Combining the
PAC and ARR decision thresholds pertaining to the total cohort or according to gender did not improve diagnostic accuracy for PA.
An ARR of <26 pmol/mIU made the diagnosis of PA highly unlikely (Fig. 3).
The ARR in healthy normotensive women (n=15) taking the OCP is shown in Fig. 4. The ARR in 2 subjects was found to be above
the reference interval for women set at <64 pmol/mIU [15] and below the newly established decision threshold for women for the
case detection of PA set at >113.6 pmol/mIU.
Fig. 1. Recruitment Schematic.
Table 1
Baseline clinical and biochemical parameters of the study cohorts.
PA EH+T2DM EH ACC; AD; PPGL OCP Healthy volunteers
Total number (n) 16 107 21 12 15 266
Men (%) 12 (75) 69 (64) 11 (52) 4 (33.3) 0 (0) 122 (46)
Age (years)* 55(26–76) 67(53–70) 54(33–72) 52(18–70) 32(23–44) 35(18–65)
Sodium (mmol/L)* 142 (140–147) 139 (132–145) 140 (135–143) 140 (138–143) 140 (136–144) 140 (135–146)
Potassium (mmol/L)* 3.7 (2.6–4.6) 4.5 (3.7–5.6) 4.3 (3.5–4.7) 4.2 (3.9–4.8) 4.0 (3.7–4.4) 4.2 (3.5–5.1)
Median (range)*.
PA=primary aldosteronism; EH=essential hypertension; T2DM=type 2 diabetes mellitus; ACC=adrenal cortical carcimona; AD=Addison's disease; PPGL=phaeo-
chromocytoma/paraganglioma; OCP=oral contraceptive pill.
Non-PA adrenal pathologies: ACC; AD; PPGL.
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4. Discussion
PA is the most frequent cause of secondary hypertension worldwide [21,22]. Early detection has the potential to prevent or
attenuate cardiovascular complications if treated appropriately [7,9,23]. Case detection necessitates the use of validated and cost-
eﬀective screening protocols [2,24]. In 1976, Dunn and Espiner [25] ﬁrst suggested the ARR as a potentially useful screening test for
PA. Five years later Hiramatsu et al. [26] proposed it as the screening test of choice for PA. Currently, the ARR is the recommended
approach for case detection of PA [2,11] in at-risk populations [3,23]. This is despite the ARR being a highly variable test, with
diagnostic sensitivity ranging from 64% to 100% and speciﬁcity from 87% to 100%. Variability of the ARR can be attributed to the
high degree of within-subject variation, diﬀerences in laboratory assays, reporting units, [27,28] pretesting patient preparation
protocols [3], the inﬂuence of medication [19,20,29,30] and the population characteristics used to establish the decision thresholds
[31]. Probably, the most important consideration regarding the interpretation of the ARR is the establishment of clinically useful
thresholds [32]. We previously established gender-speciﬁc reference intervals for PAC, DRC and ARR using the IDS-iSYS® system
for plasma aldosterone and renin [15]. In the present study, we evaluated the diagnostic performance of these tests for PA in males
and females. Evaluating diagnostic tests in a group of patients already known to have the disease and in a group of healthy volunteers
can lead to overestimation of diagnostic accuracy [33,34]. Hence, we assessed the clinical utility of the IDS-iSYS® PAC, DRC and
ARR for PA in a population that included patients in whom it was reasonable to suspect PA (i.e., patients with hypertension and
various adrenal pathologies).
In accordance with the literature, ROC curve analysis determined the ARR to be more sensitive and speciﬁc than screening by
either determination (renin or aldosterone) considered singly [26,35,36]. In our population, the ARR cut-oﬀ in males and females of
>37.4 pmol/mIU provided a diagnostic sensitivity and speciﬁcity of 100% and 96%, respectively with a positive likelihood ratio for
PA of 23:1. This ARR threshold value for PA is consistent with that of Manolopoulou et al. [12], using these same assays in healthy
Direct Renin (mIU/L) Aldosterone (pmol/L) ARR (pmol/mIU)
All
Female
Male
AUC=0.99
*DRC≤4.5
AUC=0.97
*DRC≤14.2
AUC=0.98
*DRC≤14.2
AUC=0.85
*PAC>239
AUC=0.93
*PAC>602
AUC=0.99
*ARR>37.4
AUC=1.0
*ARR>113.6
AUC=0.87
*PAC>239
AUC=1.0
*ARR >26.1
Fig. 2. Receiver Operator Characteristic (ROC) curves for direct renin concentration (DRC) (mIU/L), plasma aldosterone concentration (PAC) (pmol/L) &
aldosterone:renin ratio ARR (pmol/mIU) in the diagnosis of primary aldosteronism for male and female participants both individually and together. AUC: area under
the curve (optimum=1.0 the curve will reach the upper left corner of the plot); when the variable under study cannot distinguish between those with and without
disease the AUC will be equal to 0.5 (the ROC curve will coincide with the diagonal). *=cut-oﬀ point.
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controls (n=147), essential hypertensives (n=152) and larger numbers of PA patients (n=93). These authors determined that an ARR
at 31 pmol/mIU discriminated between EH and PA subjects with a diagnostic sensitivity and speciﬁcity of 98.9% and 78.9%,
respectively [12]. Moreover, our study conﬁrms the previous clinical validation of considerably lower ARR cut-oﬀ values with these
newly developed immunoassays [12] to that currently recommended by the ESCPG [2]. The import being the risk of false negative
classiﬁcation if laboratories using these assays apply the proposed ESPCG cut-oﬀ of 103 pmol/mIU [14].
Perhaps most useful to clinicians in clinical practice is the ﬁnding that in our population an ARR of <26 pmol/mIU irrespective
of gender, makes the diagnosis of PA highly unlikely (Fig. 3). In men and women, the DRC ROC curve analyses (AUC=0.97)
demonstrated the high predictive power of this biochemical marker to select out those patients without PA. A cut-oﬀ for DRC
≤14.2 mIU/L resulted in a diagnostic sensitivity and speciﬁcity of 100% and 84%, respectively and likelihood ratio of 6.2:1. In
females, a cut-oﬀ for PAC of >602 pmol/L resulted in a likelihood ratio for PA of 7.7:1 (diagnostic sensitivity and speciﬁcity of 100%
and 87%, respectively). Notably, stratiﬁcation of the ARR according to gender resulted in perfect discrimination (optimum AUC of
1.0) and improved diagnostic accuracy at decision thresholds for men: >26.1 pmol/mIU and women: >113.6 pmol/mIU resulting
in diagnostic sensitivity and speciﬁcity of 100%. Despite the correct characterization of all our patients with PA (n=16) we do
acknowledge that the numbers are relatively small and that only 4 of these 16 patients were women. Hence, before the thresholds
presented here could be recommended for implementation into routine clinical use further validation through prospective study with
a larger PA cohort is required.
Of interest, in our study two healthy normotensive women taking the OCP had an ARR above the reference interval for women
set at <64 pmol/mIU [15], and below the newly established PA decision threshold for women set at >113.6 pmol/mIU (Fig. 4). Both
were taking an OCP preparation containing drospirenone/ethinylestradiol. Drospirenone (a progestogenic agent), like endogenous
progesterone, acts as a potent mineralocorticoid receptor antagonist [37]. This is consistent with the ﬁndings of Pizzolo et al. [38],
who previously reported an elevated ARR in a 34 year old normotensive woman also taking a combined preparation of drospirenone
and ethinylestradiol and tested on day 28 of her cycle with renin measured as concentration. The ARR in the latter woman
normalised when the OCP was withdrawn. False-positive ARRs have been found in normal women tested during the luteal phase of
their menstrual cycle when measurement of renin concentration is used. [38,39] This serves to illustrate the importance of
understanding the clinical and biochemical context of the tests being interpreted and in particular the inﬂuence of medications. We
suggest that, when using DRC to calculate the ARR, ovulating females should be screened during the follicular phase of the
menstrual cycle. Moreover, the ARR must be interpreted with caution in individuals taking the OCP or hormone replacement
therapy. This necessitates evaluation of the pharmacological content of the medication, mode of administration, and the method of
measurement of renin prior to screening [3,30,40,41]. Cessation of oral contraceptives (minimum period of 6 weeks) in advance of
further screening should only be considered when other eﬀective measures can be taken to avoid an unwanted pregnancy [41].
There is overlap in the ARR between individuals with and without PA. The use of a single cut-point value for the ARR to
determine whether a test is considered positive or negative should not exclude evaluation of the pre-test probability of PA, and the
Table 2
Matrix table showing DRC, PAC & ARR in patients with PA, EH, non-PA adrenal pathologies (AD; PPGL; ACC) & healthy volunteers. Abbreviations as Figure 2 and
Table 1.
Study cohorts Test PA (n=16) EH+T2DM
(n=107)
EH (n=21) OCP (n=15) ACC; AD; PPGL.
(n=12)
Healthy volunteers
(n=266)
PA DRC 6.3 (1.8–14.2)
PAC 637 (241–2000)
ARR 86 (37.7–1111)
EH+T2DM DRC <0.001 122.8 (6.5–550)
PAC <0.001 210 (102–877)
ARR <0.001 2.1 (0.2–22.3)
EH DRC <0.001 <0.001 12.5 (4.3–61.2)
PAC <0.001 0.448 177(102–341)
ARR <0.001 <0.001 11.3 (3.8–57.8)
OCP DRC <0.001 <0.001 0.092 26.5 (6.2–96.7)
PAC 0.423 <0.001 0.005 490 (113.6–
3091)
ARR <0.001 <0.001 0.025 18.3 (3.0–80.9)
ACC; AD; DRC <0.001 0.009 0.002 0.167 32.7 (7.8–550)
PPGL PAC <0.001 0.011 0.041 0.001 106 (102–701)
ARR <0.001 0.009 0.056 0.003 6.1 (0–16.8)
Healthy volunteers DRC <0.001 <0.001 <0.001 0.437 0.18 27 (3.5–113.2)
PAC <0.001 <0.001 <0.001 0.054 <0.001 293 (102–2063)
ARR <0.001 <0.001 0.64 0.004 0.036 12 (0.9–113.6)
Median (range) along diagonal; p-values below diagonal; DRC mIU/L; PAC pmol/L; ARR pmol/mIU.
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independent assessment of PAC and DRC. It is essential when interpreting the ARR that physicians and laboratory specialists do so
in the context of the clinical presentation (family history, the degree of hypertension, resistance to and response to antihypertensive
medications, the presence of any electrolyte abnormalities and/or an adrenal adenoma) [27] with special attention paid to the
analytical methods used, the inﬂuence of medications, posture, dietary salt intake and gender.
It is imperative to appreciate that the uncritical adoption of the ESCPG cut-oﬀs may lead to patient misclassiﬁcation [14].
Laboratories should only use cut-oﬀs from the literature when using analytical methods that are identical to those of the published
studies [27]. Further, literature-sourced cut-oﬀs require validation in the local population. The lack of internationally accepted pre-
testing patient preparation criteria, accepted standardised analytical methodologies, standard reference materials and assay
reporting units obligates the continued use of method-speciﬁc reference intervals for PAC, DRC and the ARR [2,3,27].
It has previously been suggested that the ARR decision thresholds between the sexes are diﬀerent [42–44]. The current study
provides evidence of signiﬁcant diﬀerences in the ARR between men and women. Should the ﬁndings presented here be
prospectively validated using a larger cohort of PA patients this will have important implications for the case detection of PA. In
young women, it will protect against the probability of inappropriately undergoing more complex, unnecessary and potentially
harmful follow-up investigations, while in men, the use of method- and gender-speciﬁc decision values will attenuate the risk of
missing a diagnosis of PA.
5. Conclusions
This study demonstrates that ARR decision thresholds for PA should not only be method-speciﬁc but gender-speciﬁc. However,
given the small number of PA (n=16) patients, in particular females (n=4), further validation through prospective study with a larger
Fig. 3. Traﬃc Light plot: green illustrates the absolute values for DRC, PAC and ARR at which study participants in our cohort did not have PA (i.e. PA is highly
unlikely), orange represents the absolute values for DRC, PAC and ARR at which some participants had and others did not have PA (i.e. PA indeterminate), orange
with shading represents “No Data” and red represents the absolute values for DRC, PAC and ARR at which all participants had PA (i.e. PA highly likely). For example,
for DRC (total cohort), all values >14.2 mIU/L are not PA, all values ≤3.5 mIU/L are PA, with values >3.5 mIU/L and ≤14.2 mIU/L indeterminate for PA. For ARR
(total cohort), all values <37.7 pmol/mIU are not PA, all values ≥37.7 pmol/mIU and ≤113.6 pmol/mIU are indeterminate for PA, and all values >113.6 pmol/mIU
are PA. The junction of the red and orange bar represents the value for the test at which it is 100% speciﬁc. The junction of the green and orange bar represents the
value for the test at which it is 100% sensitive. Once validated in other cohorts, traﬃc light plots maybe a useful tool to aid in the interpretation of DRC, PAC and ARR.
Abbreviations as Fig. 2.
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PA cohort is required before the thresholds presented here could be recommended for routine clinical use. Notwithstanding, it
suggests the validity of the recently established gender-speciﬁc reference intervals for the IDS-iSYS® ARR in our population [15].
Hence, we advocate that the ESCPG recommend the adaptation of method- and gender-speciﬁc reference intervals for PAC, DRC and
the ARR. Furthermore, we advocate the inclusion of the ARR cut-oﬀ values established using these newly developed automated
assays into future Endocrine Society guidelines for the diagnosis of PA.
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